Patent US5628781A successfully refreshed from Google Patents.
US5628781A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Implant materials, methods of treating the surface of implants with microvascular endothelial cells, and the treated implants themselves
Assignee: Thomas Jefferson University
•
Filing: 1992-09-29
•
Granted: 1997-05-13
•
Expires: 2012-09-29
Abstract
Abstract Implant materials having porosity are provided by the present invention. Methods for treating a synthetic or naturally occurring implant, such as a vascular graft, intended for implantation in a human patient are also provided comprising obtaining human microvascular fat tissue, homogenizing the fat tissue to provide a cellular slurry, and applying the cellular slurry onto said implant to provide at least 50% confluence of said cells on the surface and/or within the pores of the implant.
Inventors
- 👤 Stuart K. Williams
- 👤 Bruce E. Jarrell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 18:53
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/28; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61L27/36; A61L27/38; A61L27/3804; A61L27/3808; A61L27/3839; A61L27/3843; A61L27/50; A61L27/507; A61L27/56
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
58 words
An implant having a lumen, the implant consisting essentially of implant material having a surface porosity of from about 1 to about 20 microns and a permeability of about 10 ml/min/cm 2 to about 40 ml/min/cm 2 wherein endothelial cells are deposited in pores of about 10 to about 20 microns of the implant material by forced deposition.
Claim 2
Dependent Claim
58 words
An implant having a lumen, the implant consisting essentially of implant material having a surface porosity of from about 1 to about 20 microns and a permeability of about 10 ml/min/cm 2 to about 40 ml/min/cm 2 wherein endothelial cells are deposited in pores of about 10 to about 20 microns of the implant material by forced deposition.
Claim 3
Dependent Claim
23 words
The implant of claim 1 in which the lumenal surface of the implant has porosity of from about 1 to about 4 microns.
Claim 4
Dependent Claim
17 words
The implant of claim 1 wherein the implant has a percent pore coverage of at least 8%.
Claim 5
Dependent Claim
16 words
The implant of claim 3 wherein the percent of pore coverage is from 12% to 16%.
Claim 6
Dependent Claim
15 words
The implant of claim 1 wherein microvascular endothelial cells are deposited on the implant surface.
Claim 7
Dependent Claim
57 words
The implant of claim 5 wherein said endothelial cells are transformed with a gene coding for a therapeutic agent selected from the group consisting of plasminogen activator, soluble CD-4, Factor VIII, Factor IX, yon Willebrand Factor, urokinase, hirudin, interferons, tumor necrosis factor, interleukins, hematopoietic growth factor, antibodies, glucocerebrosidase, ADA, phenylalanine, hydroxylase, human growth hormone, insulin and erythropoietin.
References Cited (Backward Citations)
US4787900A
Cited
US4970298A
Cited
US4678468A
Cited
US4932964A
Cited
US5171261A
Cited
US5336615A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-05-12 | 2000-11-11 | 2001-05-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-05-12 | 2004-11-11 | 2005-05-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-05-12 | 2008-11-11 | 2009-05-13 | $7700.00 | Window Closed / Lapsed |